Significados de t-705 en inglés

In contrast, T-705 acts as a potent and GTP-competitive inhibitor of the viral polymerase.

T-705 (favipiravir) is a new antiviral agent in advanced clinical development for influenza therapy.

Influenza virus-infected cell cultures were exposed to T-705 or ribavirin during single or serial virus passaging.

This mutagenic effect is 2-fold higher for T-705 than for ribavirin.

Whereas neuraminidase inhibitors slow down viral replication, T-705 is a viral RNA polymerase inhibitor which prevents viral replication.

These mechanisms were also proposed for ribavirin, an established and broad antiviral drug that shares structural similarity with T-705.

We here performed a comparative analysis of the effects of T-705 and ribavirin on influenza virus and host cell functions.

T-705 is also currently in phase I trials in Japan where it has been put on the Health Ministry's priority list for development.

Survival and virological characteristics were observed for 85 patients in the control group and 39 in the T-705 treatment group.